. 2016 Aug 31;6:188. doi: 10.3389/fonc.2016.00188

Table 2.

Some of the meta-clusters characteristic of AML for the 23 AML samples in the training set.

Tube	Marker expression	#Samples	Fraction of cells
2	Kappa^lowLambda^lowCD19⁺CD20⁻	5	63% (±6.8)
3	CD7⁺CD4⁻CD8⁻CD2⁻	4	18.0% (±4.8)
4	CD15⁻CD13⁺CD16⁻CD56⁻	17	16.6% (±6.9)
4	CD15⁻CD13⁺CD16⁻CD56⁺	8	11.1% (±5.7)
5	CD14⁻CD11c⁻CD64⁻CD33⁺	10	13.5% (±5.2)
5	CD14⁻CD11c⁺CD64⁻CD33⁺	18	10.8% (±3.8)
5	CD14^lowCD11c⁺CD64^lowCD33⁺	6	13.8% (±4.3)
6	HLA-DR⁺CD117⁺CD34⁺CD38⁺	11	13.3% (±2.6)
6	HLA-DR⁺CD117^±CD34⁺CD38⁺	13	17.3% (±6.6)
6	HLA-DR⁻CD117^±CD34⁻CD38⁺	5	12.9% (±4.7)
7	CD5⁻CD19⁺CD3⁻CD10⁻	3	12.3% (±2.4)
7	CD5⁺CD19⁻CD3⁻CD10⁻	3	10.0% (±8.5)
7	CD5⁻CD19⁻CD3⁻CD10⁺	1	9.9%

In the second column, “−,” “low,” and “+” denote very low, low, and high, abundance of a marker, respectively, and ± denotes a marker that is positively expressed by some samples and negatively expressed by others. The number of samples participating in a meta-cluster is shown in the third column. The average fraction of cells in a sample participating in a meta-cluster and the SD are shown in the fourth column.